eFFECTOR Therapeutics Boosts Series B To $56M

San Diego-based eFFECTOR Therapeutics, which is developing gene translation technology to help in the treatment of cancer, has boosted its Series B funding to $56M, the company said Friday. The company--which raised $40M in the round back in December--said the new funding came from Sectoral Asset Management. Maha Katabi, Ph.D., CFA at Sectoral has joined the company's board as part of the funding. The company said the funding will go towards clinical development of its lead product. The company's other investors include Altitude Life Science Ventures, AbbVie Biotech Ventures, BioMed Ventures, Abingworth, Novartis Venture Fund, SR One, The Column Group, US Venture Partners, Astellas Ventures, Osage University Partners and Mission Bay Capital. The new funding brings the company's total raised to $101M. More information »